General MedicationsINJECTIONStandard
ZINBRYTA
DACLIZUMAB
Standard Dose
150MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview ZINBRYTA is listed in Drugs@FDA under application 761029 (BLA).
Review priority: N/A Marketing status: Prescription Active ingredient DACLIZUMAB Form and strength INJECTABLE;INJECTION - 150MG/ML Sponsor BIOGEN Submission history Latest submission status date: 2017-11-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview ZINBRYTA is listed in Drugs@FDA under application 761029 (BLA). Review priority: N/A Marketing status: Prescription Active ingredient DACLIZUMAB Form and strength INJECTABLE;INJECTION - 150MG/ML Sponsor BIOGEN Submission history Latest submission status date: 2017-11-01 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.